ファーバー病の世界市場レポート 2025年

ファーバー病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.7％で24億8,000万米ドルに成長します。予測期間の成長は、標的治療薬のパイプラインの拡大、政府による優遇措置や希少疾病用医薬品の指定の増加、専門的ヘルスケアサービスへの幅広いアクセス、希少疾病に特化したバイオベンチャー企業への投資の増加、次世代シーケンサーの利用拡大などに起因しています。この期間に予想される主な動向には、遺伝子治療技術の進歩、希少疾患の診断に向けた人工知能の統合、テクノロジーを活用したバイオマーカー探索、酵素補充療法の進歩、新生児スクリーニングプログラムの改善などがあります。

希少遺伝性疾患の有病率の増加は、今後数年間のファーバー病市場の成長を促進すると予想されます。希少遺伝性疾患は、個人のDNAの突然変異によって引き起こされる遺伝性の疾患で、人口のごく一部に影響を及ぼします。このような有病率の増加は、診断技術の進歩により、以前は診断されなかったり誤診されたりしていた疾患をより早く正確に発見できるようになったことが主な原因です。ファーバー病は、標的治療の開発モデルとして機能し、超希少疾患の酵素補充治療の研究を支援することで、希少遺伝性疾患の増加に対処する上で重要な役割を果たしています。例えば、2022年11月、オーストラリア政府保健・高齢者医療省は、1万人に5人未満が罹患すると定義される希少疾患は、人口の8％にあたる約200万人に影響を与え、7,000以上の慢性疾患または生命を脅かす疾患が知られていると報告しました。したがって、希少遺伝性疾患の有病率の上昇がファーバー病市場の拡大に寄与しています。

臨床試験への投資の増加は、今後数年間のファーバー病市場の成長を促進すると予想されます。臨床試験とは、医薬品、治療、医療機器などの医療介入の安全性、有効性、結果を評価するためにヒトを対象に実施される調査です。このような投資の拡大には、医学の進歩、個別化医療、満たされていないヘルスケア課題に対処する差し迫った必要性などが拍車をかけ、革新的な治療法に対する需要が高まっていることが背景にあります。ファーバー病は、希少で十分なサービスを受けていない遺伝性疾患に焦点を当てた調査の必要性を強調することで、このような投資の重要性を強調しています。例えば、2024年10月、米国を拠点とする製薬情報ソリューションのプロバイダーであるCiteline社は、TrialTroveが2024年に少なくとも1つの薬剤を含む9,959件の第I-III相臨床試験を開始する予定であると報告した（2023年比9.4％増）。このように、臨床試験への投資の拡大がファーバー病市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のファーバー病：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のファーバー病市場：成長率分析
• 世界のファーバー病市場の実績：規模と成長、2019年～2024年
• 世界のファーバー病市場の予測：規模と成長、2024年～2029年、2034年
• 世界のファーバー病：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のファーバー病市場：ファーバー病タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 古典的ファーバー病
• 非古典的ファーバー病
• 世界のファーバー病市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 酵素補充療法
• 治療
• 遺伝子治療
• 骨髄移植
• 支持療法
• 世界のファーバー病市場：臨床症状別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 関節の障害と変形
• 難聴
• 呼吸困難
• 皮膚症状
• 世界のファーバー病市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 専門クリニック
• 診断センター
• その他のエンドユーザー
• 世界のファーバー病市場、古典的ファーバー病の病型別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 1型重症乳児型
• タイプ2中間型小児型
• タイプ3若年発症型
• 世界のファーバー病市場、非古典的ファーバー病の病型別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• タイプ4神経優位型
• タイプ5内臓優位型
• タイプ6心肺障害フォーム

第7章 地域別・国別分析

• 世界のファーバー病市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のファーバー病市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ファーバー病市場：競合情勢
• ファーバー病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Mount Sinai Health System Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Emory Healthcare
• Kyowa Kirin Co. Ltd.
• BioMarin Pharmaceutical Inc.
• Children's National Hospital
• Medanta-The Medicity（Global Health Ltd.）
• Amicus Therapeutics Inc.
• JCR Pharmaceuticals Co. Ltd.
• Spark Therapeutics Inc.
• REGENXBIO Inc.
• Passage Bio Inc.
• Protalix BioTherapeutics Inc.
• Medicover Hospitals
• Minoryx Therapeutics S.L.
• bluebird bio Inc.
• Avrobio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ファーバー病市場2029年：新たな機会を提供する国
• ファーバー病市場2029年：新たな機会を提供するセグメント
• ファーバー病市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Farber's disease is a rare inherited disorder resulting from a deficiency of the enzyme acid ceramidase, which causes fatty substances to build up in body tissues. It is passed down through an autosomal recessive pattern and usually appears during infancy. Common symptoms include joint deformities, subcutaneous nodules, and a gradual decline in neurological function. The disease progresses over time and can be life-threatening, necessitating coordinated care and symptom-focused treatment.

Farber's disease primarily exists in two forms: classical and non-classical. The classical form is the most common type and is marked by early-onset symptoms such as joint abnormalities, subcutaneous nodules, and progressive neurological deterioration. Available treatments include enzyme replacement therapy, gene therapy, symptomatic management, bone marrow transplantation, and supportive interventions for symptoms like joint issues, hearing loss, respiratory problems, and skin-related conditions. Key end-users include hospitals, specialized clinics, diagnostic facilities, and others.

The farber's disease market research report is one of a series of new reports from The Business Research Company that provides farber's disease market statistics, including the farber's disease industry global market size, regional shares, competitors with the farber's disease market share, detailed farber's disease market segments, market trends, and opportunities, and any further data you may need to thrive in the farber's disease industry. This farber's disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The farber's disease market size has grown strongly in recent years. It will grow from $1.87 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be credited to increasing awareness and diagnosis rates, greater adoption of genetic testing, a rise in research efforts focused on lysosomal storage disorders, the expansion of rare disease registries, and growing support from patient advocacy organizations.

The farber's disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the expanding pipeline of targeted therapies, increasing government incentives and orphan drug designations, broader access to specialized healthcare services, rising investments in rare disease-focused biotech startups, and the growing use of next-generation sequencing. Key trends expected during this period include progress in gene therapy technologies, the integration of artificial intelligence for diagnosing rare diseases, technology-enabled biomarker discovery, advancements in enzyme replacement therapies, and improvements in newborn screening programs.

The increasing prevalence of rare genetic disorders is anticipated to drive the growth of the Farber's disease market in the coming years. Rare genetic disorders are inherited conditions caused by mutations in an individual's DNA, affecting a very small portion of the population. This rise in prevalence is largely attributed to advancements in diagnostic technologies that allow for earlier and more accurate detection of conditions that were previously undiagnosed or misdiagnosed. Farber's disease plays a significant role in addressing the rise in rare genetic disorders by acting as a model for the development of targeted therapies and supporting research in enzyme replacement treatments for ultra-rare conditions. For example, in November 2022, the Australian Government Department of Health and Aged Care reported that rare diseases-defined as affecting fewer than 5 in 10,000 people-impact around 2 million individuals, or 8% of the population, with over 7,000 known chronic or life-threatening conditions. Hence, the rising prevalence of rare genetic diseases is contributing to the expansion of the Farber's disease market.

The rising investment in clinical trials is expected to drive the growth of the Farber's disease market in the coming years. Clinical trials are research studies conducted in humans to assess the safety, effectiveness, and outcomes of medical interventions, including drugs, treatments, or medical devices. This growing investment is fueled by the increasing demand for innovative therapies, spurred by advancements in medical science, personalized medicine, and the pressing need to address unmet healthcare challenges. Farber's disease underscores the importance of such investments by emphasizing the need for research focused on rare and underserved genetic disorders. For example, in October 2024, Citeline, a US-based provider of pharmaceutical intelligence solutions, reported that TrialTrove recorded 9,959 Phase I-III clinical trials set to begin in 2024 involving at least one drug-a 9.4% rise compared to 2023. Thus, the growing investment in clinical trials is contributing to the expansion of the Farber's disease market.

In September 2022, Idera Pharmaceuticals, a biotechnology company based in the US, acquired Aceragen for an undisclosed sum. This acquisition was intended to strengthen Idera Pharmaceuticals' position in the rare disease market by adding Aceragen's pipeline to its portfolio, including ACG-801, a therapy in development for Farber's disease. The move aims to address a significant unmet medical need and accelerate the advancement of enzyme replacement therapies. Aceragen Inc., also a US-based biopharmaceutical company, is actively developing ACG-801, an enzyme replacement therapy designed specifically to treat Farber disease, a rare lysosomal storage disorder.

Major players in the farber's disease market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Mount Sinai Health System, Emory Healthcare, Kyowa Kirin Co. Ltd., BioMarin Pharmaceutical Inc., Children's National Hospital, Medanta - The Medicity (Global Health Ltd.), Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Spark Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Protalix BioTherapeutics Inc., Medicover Hospitals, Minoryx Therapeutics S.L., bluebird bio Inc., and Avrobio Inc.

North America was the largest region in the farber's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in farber's disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the farber's disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The farber's disease market includes revenues earned by rehabilitation services, nutritional support services, and clinical trial access services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Farber's Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on farber's disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for farber's disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The farber's disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Farber's Disease: Classical Farber's Disease; Non-Classical Farber's Disease
• 2) By Treatment: Enzyme Replacement Therapy; Symptomatic Treatment; Gene Therapy; Bone Marrow Transplant; Supportive Care
• 3) By Clinical Symptoms: Joint Involvement And Deformities; Hearing Loss; Respiratory Distress; Dermatological Manifestations

4 By End-User: Hospitals; Specialty Clinics; Diagnostic Centers; Other End-Users

• Subsegments:
• 1) By Classical Farber's Disease: Type 1 Severe Infantile Form; Type 2 Intermediate Childhood Form; Type 3 Juvenile-Onset Form
• 2) By Non-Classical Farber's Disease: Type 4 Neurological Predominant Form; Type 5 Visceral Predominant Form; Type 6 Cardiopulmonary Involvement Form
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Mount Sinai Health System
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Farber's Disease Market Characteristics

3. Farber's Disease Market Trends And Strategies

4. Farber's Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Farber's Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Farber's Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Farber's Disease Market Growth Rate Analysis
• 5.4. Global Farber's Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Farber's Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Farber's Disease Total Addressable Market (TAM)

6. Farber's Disease Market Segmentation

• 6.1. Global Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical Farber's Disease
• Non-Classical Farber's Disease
• 6.2. Global Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapy
• Symptomatic Treatment
• Gene Therapy
• Bone Marrow Transplant
• Supportive Care
• 6.3. Global Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Joint Involvement And Deformities
• Hearing Loss
• Respiratory Distress
• Dermatological Manifestations
• 6.4. Global Farber's Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Other End-Users
• 6.5. Global Farber's Disease Market, Sub-Segmentation Of Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Severe Infantile Form
• Type 2 Intermediate Childhood Form
• Type 3 Juvenile-Onset Form
• 6.6. Global Farber's Disease Market, Sub-Segmentation Of Non-Classical Farber's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 4 Neurological Predominant Form
• Type 5 Visceral Predominant Form
• Type 6 Cardiopulmonary Involvement Form

7. Farber's Disease Market Regional And Country Analysis

• 7.1. Global Farber's Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Farber's Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Farber's Disease Market

• 8.1. Asia-Pacific Farber's Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Farber's Disease Market

• 9.1. China Farber's Disease Market Overview
• 9.2. China Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Farber's Disease Market

• 10.1. India Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Farber's Disease Market

• 11.1. Japan Farber's Disease Market Overview
• 11.2. Japan Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Farber's Disease Market

• 12.1. Australia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Farber's Disease Market

• 13.1. Indonesia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Farber's Disease Market

• 14.1. South Korea Farber's Disease Market Overview
• 14.2. South Korea Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Farber's Disease Market

• 15.1. Western Europe Farber's Disease Market Overview
• 15.2. Western Europe Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Farber's Disease Market

• 16.1. UK Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Farber's Disease Market

• 17.1. Germany Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Farber's Disease Market

• 18.1. France Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Farber's Disease Market

• 19.1. Italy Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Farber's Disease Market

• 20.1. Spain Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Farber's Disease Market

• 21.1. Eastern Europe Farber's Disease Market Overview
• 21.2. Eastern Europe Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Farber's Disease Market

• 22.1. Russia Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Farber's Disease Market

• 23.1. North America Farber's Disease Market Overview
• 23.2. North America Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Farber's Disease Market

• 24.1. USA Farber's Disease Market Overview
• 24.2. USA Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Farber's Disease Market

• 25.1. Canada Farber's Disease Market Overview
• 25.2. Canada Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Farber's Disease Market

• 26.1. South America Farber's Disease Market Overview
• 26.2. South America Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Farber's Disease Market

• 27.1. Brazil Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Farber's Disease Market

• 28.1. Middle East Farber's Disease Market Overview
• 28.2. Middle East Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Farber's Disease Market

• 29.1. Africa Farber's Disease Market Overview
• 29.2. Africa Farber's Disease Market, Segmentation By Type Of Farber's Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Farber's Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Farber's Disease Market, Segmentation By Clinical Symptoms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Farber's Disease Market Competitive Landscape And Company Profiles

• 30.1. Farber's Disease Market Competitive Landscape
• 30.2. Farber's Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mount Sinai Health System Overview, Products and Services, Strategy and Financial Analysis

31. Farber's Disease Market Other Major And Innovative Companies

• 31.1. Emory Healthcare
• 31.2. Kyowa Kirin Co. Ltd.
• 31.3. BioMarin Pharmaceutical Inc.
• 31.4. Children's National Hospital
• 31.5. Medanta - The Medicity (Global Health Ltd.)
• 31.6. Amicus Therapeutics Inc.
• 31.7. JCR Pharmaceuticals Co. Ltd.
• 31.8. Spark Therapeutics Inc.
• 31.9. REGENXBIO Inc.
• 31.10. Passage Bio Inc.
• 31.11. Protalix BioTherapeutics Inc.
• 31.12. Medicover Hospitals
• 31.13. Minoryx Therapeutics S.L.
• 31.14. bluebird bio Inc.
• 31.15. Avrobio Inc.

32. Global Farber's Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Farber's Disease Market

34. Recent Developments In The Farber's Disease Market

35. Farber's Disease Market High Potential Countries, Segments and Strategies

• 35.1 Farber's Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Farber's Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Farber's Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer